Suppr超能文献

轻度痴呆和阿尔茨海默病中神经血管功能障碍的脑脊液生物标志物

Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease.

作者信息

Sweeney Melanie D, Sagare Abhay P, Zlokovic Berislav V

机构信息

Department of Physiology and Biophysics, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

出版信息

J Cereb Blood Flow Metab. 2015 Jul;35(7):1055-68. doi: 10.1038/jcbfm.2015.76. Epub 2015 Apr 22.

Abstract

Alzheimer's disease (AD) is the most common form of age-related dementias. In addition to genetics, environment, and lifestyle, growing evidence supports vascular contributions to dementias including dementia because of AD. Alzheimer's disease affects multiple cell types within the neurovascular unit (NVU), including brain vascular cells (endothelial cells, pericytes, and vascular smooth muscle cells), glial cells (astrocytes and microglia), and neurons. Thus, identifying and integrating biomarkers of the NVU cell-specific responses and injury with established AD biomarkers, amyloid-β (Aβ) and tau, has a potential to contribute to better understanding of the disease process in dementias including AD. Here, we discuss the existing literature on cerebrospinal fluid biomarkers of the NVU cell-specific responses during early stages of dementia and AD. We suggest that the clinical usefulness of established AD biomarkers, Aβ and tau, could be further improved by developing an algorithm that will incorporate biomarkers of the NVU cell-specific responses and injury. Such biomarker algorithm could aid in early detection and intervention as well as identify novel treatment targets to delay disease onset, slow progression, and/or prevent AD.

摘要

阿尔茨海默病(AD)是与年龄相关的痴呆症最常见的形式。除了遗传、环境和生活方式外,越来越多的证据支持血管因素对包括因AD所致痴呆症在内的痴呆症的影响。阿尔茨海默病会影响神经血管单元(NVU)内的多种细胞类型,包括脑血管细胞(内皮细胞、周细胞和血管平滑肌细胞)、神经胶质细胞(星形胶质细胞和小胶质细胞)以及神经元。因此,识别并整合NVU细胞特异性反应和损伤的生物标志物与已有的AD生物标志物淀粉样β蛋白(Aβ)和tau,有可能有助于更好地理解包括AD在内的痴呆症的疾病进程。在此,我们讨论关于痴呆症和AD早期阶段NVU细胞特异性反应的脑脊液生物标志物的现有文献。我们认为,通过开发一种纳入NVU细胞特异性反应和损伤生物标志物的算法,已有的AD生物标志物Aβ和tau的临床实用性可能会得到进一步提高。这样的生物标志物算法有助于早期检测和干预,以及识别新的治疗靶点,以延缓疾病发作、减缓疾病进展和/或预防AD。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21df/4640280/3046b117ba67/jcbfm201576f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验